Holding(s) in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Southern Cross Healthcare Group Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

NO

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

NO

An event changing the breakdown of voting rights

NO

Other (please specify):

NO

3. Full name of person(s) subject to the notification obligation: iii

Breeden European Ventures LLC (Indirect)

4. Full name of shareholder(s)  (if different from 3.):iv

Breeden European Partners (California) L.P. (direct)

5. Date of the transaction and date on which the threshold is crossed or reached: v

15 January 2010

6. Date on which issuer notified:

19 January 2010

7. Threshold(s) that is/are crossed or reached: vi, vii

3%

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B14RYC39

5,613,591

5,613,591

5,763,591

5,763,591

3.06%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/  Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

5,763,591

3.06%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

5,763,591 shares (3.06%) are held by Breeden European Partners (California) L.P.; a Limited Partnership, whose General Partner is Breeden European Capital Partners LLC, whose managing member is Richard C. Breeden & Co International LLC, whose managing member is Richard C. Breeden (Indirect Interests).

Breeden European Ventures LLC whose managing member is Richard C. Breeden has an indirect interest in the voting rights of 5,763,591 shares (3.06%) in its capacity as discretionary investment manager of Breeden European Partners (California) L.P.

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Nandita Hogan. Breeden European Ventures LLC or alternatively Ben Barnett, Breeden European Capital Management LLP

15. Contact telephone number:

 +1 (203) 618-0065 or alternatively, +44 (0) 203 170 5518